Statins muscle pain has long troubled some patients who rely on cholesterol-lowering drugs to prevent cardiovascular disease. While statins reduce heart attack and stroke risk for millions, a subset of users report muscle soreness or weakness, and a small fraction suffer severe muscle breakdown that can endanger the kidneys.
Statins muscle pain linked to a calcium leak
Scientists at the University of British Columbia, working with collaborators at the University of Wisconsin-Madison, report a molecular explanation for these effects. The findings, published in Nature Communications, outline how statins alter a key calcium channel in muscle cells, a discovery that could help drug makers design safer therapies that preserve cholesterol benefits while limiting harm to muscle tissue.
How statins disrupt calcium control
The team used cryo-electron microscopy to examine the ryanodine receptor 1, or RyR1, a protein that governs calcium movement inside skeletal muscle fibers. Under normal conditions, RyR1 opens and closes to release calcium for contraction, then restores balance.
The researchers found that statins can interfere with this gating by keeping the channel in an open state. The result is a persistent calcium leak into areas that require strict control, creating conditions that can injure muscle cells.
Lead author Dr. Steven Molinarolo, a postdoctoral researcher in UBC’s department of biochemistry and molecular biology, said the imaging revealed in near-atomic detail how statins attach to the channel. He said the resulting calcium leak helps account for muscle pain in some patients and, in rare cases, life-threatening complications.
Three-molecule binding explains channel activation
The researchers focused on atorvastatin, a widely prescribed statin, and concluded that similar interactions may occur across the drug class. A notable insight was the way the drug engages a pocket in the RyR1 protein.
One statin molecule binds when the channel is closed, increasing the likelihood it will open. Two additional molecules then occupy the same pocket, stabilizing the open state and allowing calcium to continue escaping.
Senior author Dr. Filip Van Petegem, a professor at UBC’s Life Sciences Institute, said the work provides a blueprint for designing statins that avoid this interaction with muscle proteins. By adjusting structural features that drive RyR1 binding, developers may be able to reduce muscle-related side effects without weakening cholesterol control.
Toward statins that are easier to tolerate
More than 200 million people worldwide use statins. Severe muscle injury is uncommon, but milder symptoms such as soreness, fatigue, and weakness are more frequent and can prompt patients to stop treatment, forfeiting important cardiovascular protection.
The new structural insights could guide the creation of statins that are better tolerated, helping more patients stay on therapy. The research relied on high-resolution imaging at UBC’s macromolecular cryo-electron microscopy facility, allowing the team to visualize precisely how statin molecules interact with RyR1.
The authors said the work links a long-standing safety concern to a specific molecular process and offers a foundation for future drug development. Statins have underpinned cardiovascular care for decades.
The researchers said their goal is to enhance safety so patients can benefit from cholesterol reduction with fewer muscle-related complications. While further studies and development are needed before new medications emerge, the findings point to a promising path for improving everyday quality of life for people who depend on these drugs.
For patients managing soreness, fatigue, or weakness after exercise, related research has investigated what science says about popular workout recovery methods. The University of British Columbia and the University of Wisconsin–Madison provide further information on their ongoing biomedical research programs.